Clinical Trial Update: Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) [Phase 1, Phase 2]

View source ↗

Summary

Substudy 01A of MK-9999-01A (LIGHTBEAM-U01) evaluates Zilovertamab Vedotin in pediatric and young adult participants with hematologic malignancies or solid tumo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Ewing Sarcoma
• Neuroblastoma

Drugs mentioned

• Zilovertamab vedotin (zilovertamab vedotin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma | Phase 1, Phase 2 | Status: RECRUITING